Search
Stomach Neoplasms Clinical Trials
A listing of 7 Stomach Neoplasms clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 7 of 7
There are currently 7 active clinical trials seeking participants for Stomach Neoplasms research studies. The states with the highest number of trials for Stomach Neoplasms participants are Guangdong, Fujian, Jiangsu and California.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Healthy Volunteer Clinical Studies
Recruiting
Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.
Conditions:
Healthy
Healthy Volunteers
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Recruiting
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Alaska Womens Cancer Care ( Site 1016), Anchorage, Alaska +71 locations
Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
Recruiting
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer.
Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are f... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California +9 locations
Conditions: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Recruiting
Background:
Gastric cancers are cancers of the stomach. Hereditary ones are passed from parent to child. Researchers want to gather data about hereditary gastric cancers. They want to learn about changes these cause in the body and about the genes involved.
Objective:
-To gather data about hereditary gastric cancer.
Eligibility:
People at least 2 years old with personal or family history with a hereditary gastric cancer.
People at least 2 years old with gene changes that lead to such cancer... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
06/08/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Stomach Neoplasms, Stomach Cancer, Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS), Hereditary Diffuse Gastric Cancer (HDGC), Familial Diffuse Gastric Cancer
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting
Background:
Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis.
Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States.
The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with s... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
06/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mesothelioma, Thymoma, Pancreatic Neoplasms, Biliary Tract Neoplasms, Stomach Neoplasms
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors
Recruiting
Background:
Certain stomach cancers are rare, but they have high mortality rates. Researchers want to learn more about gastric (stomach) tumors. In this study, they want to collect data from people who have stomach cancer or are at risk to get it. This data will be used to see if the people can be in other studies.
Objective:
To study tissue from stomach tumors and find people eligible for more studies on gastric cancer.
Eligibility:
Age greater than or equal to 2 years old who have or may... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
06/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Stomach Neoplasms, Stomach Cancer
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Recruiting
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: City of Hope, Duarte, California +9 locations
Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
A Study of SGN-B6A in Advanced Solid Tumors
Recruiting
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors.
The study will have four parts.
Part A of the study will find out how much sigvotatug vedotin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Florida Cancer Specialists - Lake Nona, Orlando, Florida +21 locations
Conditions: Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Carcinoma, Non-small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms, HER2 Negative Breast Neoplasms, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
1 - 7 of 7